MedPath

Severe Male Factor Infertility Management

Not Applicable
Conditions
Oligoasthenoteratozoospermia
Interventions
Other: Antioxidant (l-cratinine) + modifiable lifestyle factors
Registration Number
NCT02752555
Lead Sponsor
Benha University
Brief Summary

This study is the first to evaluate the effect of oral supplementation with antioxidants combined with lifestyle modification for severe male factor partner of couples undergoing ICSI.

Detailed Description

Patients underwent a therapy of a three-month period of treatment with either oral L-carnitine only (2g daily) or oral carnitine (2g daily) combined with modifiable lifestyle factors.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • Long protocol for ovulation
  • Oligoasthenoteratozoospermic male partner ( (count < 0.5 million/ml, Motility=< 40% Progressive motility =<10 %, Abnormal forms >99%).
  • Fresh semen samples.
Exclusion Criteria
  • Day 3 embryo transfer
  • Incomplete ICSI cycles
  • Endometrial thickness> 7mm

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Antioxidant+modifiable lifestyle factorsAntioxidant (l-cratinine) + modifiable lifestyle factorsIn the study group, all patients underwent a double-blind therapy of a six-month period of treatment with oral carnitine (2g daily) combined with modifiable lifestyle factors. Patients were requested to follow a healthy standard diet, avoid excessive heat exposure, avoid or minimize exposure to pollutants, and stop smoking, coffee, alcohol, and drugs uptake.After this period, all patients will undergo conventional ICSI.
Primary Outcome Measures
NameTimeMethod
Implantation rateone month
Clinical pregnancy ratetwo weeks
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

Dar Almaraa fertility and gynacology center

🇪🇬

Cairo, Egypt

Nile badrawi Hospital

🇪🇬

Cairo, Egypt

Elite fertility care center

🇪🇬

Cairo, Egypt

© Copyright 2025. All Rights Reserved by MedPath